en · de · es · fr · pt
cjc-1295-notes.peptides6608.com › Faq › Receptor Action And Clearance — Common Mistakes

Receptor Action And Clearance — Common Mistakes

By Editorial Desk · published 2025-10-13 · last reviewed 2025-11-03 · Faq

The short version of DAC linker fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.

Receptor Action and Clearance

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Identity and Naming History

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorPresent on pituitary somatotroph cells
Signal pathwayGs, cyclic AMP, protein kinase ASequence follows receptor activation
Main measured effectGrowth hormone releaseInsulin-like growth factor 1 shifts indirectly
Half-life, binding formSeveral daysExtended through serum albumin association
Half-life, unmodified formAbout 30 minutesLimited mainly by enzymatic cleavage

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Related pages on this site

Compound Identity and Development History

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

Reference notes

The science of blood transfusion dates to the first decade of the 20th century, with the discovery of distinct blood types leading to the practice of mixing some blood from the donor and the receiver before the transfusion (an early form of cross-matching). In the early 19th century, British obstetrician James Blundell made efforts to treat hemorrhage by transfusion of human blood using a syringe. In 1818, after experiments with animals, he performed the first successful transfusion of human blood to treat postpartum hemorrhage at Guy's Hospital in London. Blundell used the patient's husband as a donor, and extracted four ounces of blood from his arm to transfuse into his wife. During the years 1825 and 1830, Blundell performed 10 transfusions, five of which were beneficial, and published his results. He also invented a number of instruments for the transfusion of blood. He made a substantial amount of money from this endeavour, roughly $2 million ($50 million real dollars). In 1840, Samuel Armstrong Lane, aided by Blundell, performed the first successful whole blood transfusion to treat haemophilia at St George's Hospital Medical School in London. However, early transfusions were risky and many resulted in the death of the patient. By the late 19th century, blood transfusion was regarded as a risky and dubious procedure, and was largely shunned by the medical establishment. Work to emulate James Blundell continued in Edinburgh. In 1845 the Edinburgh Journal described the successful transfusion of blood to a woman with severe uterine bleeding.

candidate gene A gene whose location on a chromosome is associated with a particular phenotype (often a disease-related phenotype), and which is therefore suspected of causing or contributing to the phenotype. Candidate genes are often selected for study based on a priori knowledge or speculation about their functional relevance to the trait or disease being researched.

I was amazed to see today in the Vorwärts an excerpt from my 'Introduction' that had been printed without my knowledge and tricked out in such a way as to present me as a peace-loving proponent of legality [at all costs]. Which is all the more reason why I should like it to appear in its entirety in the Neue Zeit in order that this disgraceful impression may be erased. I shall leave Liebknecht in no doubt as to what I think about it and the same applies to those who, irrespective of who they may be, gave him this opportunity of perverting my views and, what's more, without so much as a word to me about it.

Medical availability and clinical practice vary across the world due to regional differences in culture and technology. Modern scientific medicine is highly developed and widespread in the Western world, whereas in some low-resource regions—including parts of Africa, the Pacific Islands of Oceania, Southeast Asia, and Latin America—populations often rely more heavily on traditional medicine. These practices consist of decentralized training structures and vary widely in empirical support; consequently, they may lack formal regulatory oversight or robust evidence for clinical efficacy. In the developed world, evidence-based medicine (EBM) is not universally applied in clinical practice; for example, a 2007 survey of literature reviews found that about 49% of medical interventions lacked sufficient evidence to support either benefit or harm. However, medical practitioners who apply an intervention with uncertain efficacy without adequate justification, transparency, or patient consent may violate the bioethical principle of non-maleficence, a core tenet of biomedical ethics historically associated with the Hippocratic Oath, which emphasizes a primary duty to "first, do no harm." In modern clinical practice, physicians and mid-level practitioners such as physician assistants personally assess patients to diagnose, prognose, treat, and prevent disease using clinical judgment. An initial medical encounter with a patient typically begins with a review of the patient's medical history and medical record, followed by a medical interview and a physical examination.

Sources: en.wikipedia.org

Reference notes

== Biotransformation == After the bite of Bungarus multicinctus the venom enters the bloodstream and enters the circulation and ends up in the central and peripheral nervous system. Since κ-bungarotoxin has a high affinity for nAChRs the venom will target the tissues rich in nAChRs. Together with its prolonged, potentially irreversible binding, there will not be much κ-bungarotoxin available in the bloodstream, but it will remain localized in the central nervous system and ganglia. Unbound nAChRs will only be available through de novo synthesis of these receptors. Though biotransformation of κ-bungarotoxin is not sufficiently researched, the long-chain three-finger toxins (3FTx) family member blocks ion channels on the postsynaptic membrane. Therefore, it is suggested that the toxin works extracellularly, and can thus not be biotransformed by the cytochrome P450 enzymes. κ-Bungarotoxin is a protein and can thus be gradually degraded by enzymes such as peptidases and lysosomes. The result will be smaller peptides and amino acids, which can be used for the synthesis of endogenous compounds. However, since the κ-bungarotoxin's affinity for the neuronal nAChR is very high, not much of the protein can be degraded before the ligand-receptor complex is formed.

The mental effects of GnRH modifiers are positive with treatment associated with significant improvements in multiple psychological measures, including global functioning, depression, and overall behavioral and/or emotional problems. In a two-year study published in January 2023, Chen et al. found that gender-affirming hormones for transgender and non-binary youth "improved appearance congruence and psychosocial functioning". Another study analyzing Dutch transgender youth completed by Catharina van der Loos et al. found that 98% of participants who started gender-affirming hormone treatment in youth continued using said treatment into adulthood. In February 2024, the American Psychological Association approved a policy statement supporting unobstructed access to health care and evidence-based clinical care for transgender, gender-diverse, and nonbinary children, adolescents, and adults, as well as opposing state bans and policies intended to limit access to such care. In May 2025, a two-year systematic review commissioned by the state of Utah as part of a ban on trans youth healthcare concluded that "The consensus of the evidence supports that the treatments are effective in terms of mental health, psychosocial outcomes, and the induction of body changes consistent with the affirmed gender in pediatric [gender dysphoria] patients. The evidence also supports that the treatments are safe in terms of changes to bone density, cardiovascular risk factors, metabolic changes, and cancer".

=== Diagnosis === In 2010, a team from New York described detection of PrPSc in sheep's blood, even when initially present at only one part in one hundred billion (10−11) in sheep's brain tissue. The method combines amplification with a novel technology called surround optical fiber immunoassay (SOFIA) and some specific antibodies against PrPSc. The technique allowed improved detection and testing time for PrPSc. In 2014, a human study showed a nasal brushing method that can accurately detect PrP in the olfactory epithelial cells of people with CJD.

Anazocine (INN; also known as azabicyclane or CS-307) is an opioid analgesic of the morphan/benzomorphan family developed in the middle 1960s in the United States which was never marketed. The structure and properties of several related α- and β-azabicyclane opioids was explored. Anazocine's chemical and structural relatives include opioid partial agonists, mixed agonist-antagonists, pure agonists, antagonists, and atypical non-opioid analgesics. It was tested in pigeons and in other experiments which contrasted and compared its analgesic effects to those of the phenazepine opioid ethoheptazine and the phenalkoxam open chain opioid propoxyphene, and pethidine as well.

Bayberry fruits provide a wax often used to make candles; Many dry fruits are used as decorations or in dried flower arrangements (e.g., annual honesty, cotoneaster, lotus, milkweed, unicorn plant, and wheat). Ornamental trees and shrubs are often cultivated for their colorful fruits, including beautyberry, cotoneaster, holly, pyracantha, skimmia, and viburnum. Fruits of opium poppy are the source of opium, which contains the drugs codeine and morphine, as well as the biologically inactive chemical thebaine from which the drug oxycodone is synthesized. Osage orange fruits are used to repel cockroaches. Many fruits provide natural dyes (e.g., cherry, mulberry, sumac, and walnut). Dried gourds are used as bird houses, cups, decorations, dishes, musical instruments, and water jugs. Pumpkins are carved into Jack-o'-lanterns for Halloween. The fibrous core of the mature and dry Luffa fruit is used as a sponge. The spiny fruit of burdock or cocklebur inspired the invention of Velcro. Coir fiber from coconut shells is used for brushes, doormats, floor tiles, insulation, mattresses, sacking, and as a growing medium for container plants. The shell of the coconut fruit is used to make bird houses, bowls, cups, musical instruments, and souvenir heads. The hard and colorful grain fruits of Job's tears are used as decorative beads for jewelry, garments, and ritual objects.

Sources: en.wikipedia.org

Notes from published material

In leagues such as the National Football League, there is a very rigorous process required to obtain an exemption to this rule even when the athlete has been medically prescribed the drug by their physician.

18B Special Forces Weapons Sergeant - SGT-SFC 18C Special Forces Engineer Sergeant - SGT-SFC 18D Special Forces Medical Sergeant - SGT-SFC 18E Special Forces Communications Sergeant - SGT-SFC 18F Special Forces Intelligence Sergeant - SSG-SFC 18X Special Forces Candidate 18Z Special Forces Senior Sergeant - MSG-CSM

=== SIMS and NanoSIMS imaging === Secondary ion mass spectrometry (SIMS) is used to analyze solid surfaces and thin films by sputtering the surface with a focused primary ion beam and collecting and analyzing ejected secondary ions. There are many different sources for a primary ion beam. However, the primary ion beam must contain ions that are at the higher end of the energy scale. Some common sources are: Cs+, O2+, O, Ar+ and Ga+. SIMS imaging is performed in a manner similar to electron microscopy; the primary ion beam is emitted across the sample while secondary mass spectra are recorded. SIMS proves to be advantageous in providing the highest image resolution but only over small area of samples. More, this technique is widely regarded as one of the most sensitive forms of mass spectrometry as it can detect elements in concentrations as small as 1012-1016 atoms per cubic centimeter. Multiplexed ion beam imaging (MIBI) is a SIMS method that uses metal isotope labeled antibodies to label compounds in biological samples. Developments within SIMS: Some chemical modifications have been made within SIMS to increase the efficiency of the process. There are currently two separate techniques being used to help increase the overall efficiency by increasing the sensitivity of SIMS measurements: matrix-enhanced SIMS (ME-SIMS) - This has the same sample preparation as MALDI does as this simulates the chemical ionization properties of MALDI. ME-SIMS does not sample nearly as much material.

=== Thermoelectric refrigeration === Thermoelectric cooling uses the Peltier effect to transfer heat when an electric current passes through junctions of dissimilar thermoelectric materials. Thermoelectric cooling is used in applications including electronic thermal management and scientific instrumentation. Thermoelectric coolers have no mechanical moving parts and can be compact and lightweight, making them useful where the size, mass or mechanical complexity of conventional refrigeration is undesirable. For larger temperature differences, thermoelectric modules can be arranged in multiple stages, with successive stages removing both the heat transferred from the cooled region and heat generated by preceding stages. The performance of a thermoelectric cooler depends on factors including thermoelectric material properties, operating temperatures, electrical current and thermal resistances. For conventional space-cooling and food-refrigeration applications, thermoelectric systems generally have a lower coefficient of performance than vapor-compression systems and therefore require more electrical input for the same cooling load.

Droëwors – a Southern African snack food, based on the traditional, coriander-seed spiced boerewors sausage. Droge worst, Dutch snack food Dambu nama, Northern Nigerian dried meat floss, made with beef and chicken

Sources: en.wikipedia.org

Frequently asked questions

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

How does the albumin-binding group alter behavior?

It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.

What do studies generally measure?

Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network